---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218225"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-05-12T12:00:17+00:00"
generated_at: "2026-05-12T12:19:23.650329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027

## Summary
- Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.
- Net loss $18M for Q1 2026 vs $17.4M in Q1 2025; R&D expenses decreased to $15.3M.
- Confirmed ORR 44% (32/72) for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer from SGO April 2026.
- FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer.
- Phase 1 results published in NEJM; NDA submission planned in Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-218225
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-05-12T12:00:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218225
- JSON: https://secwatch.observer/filing/0001193125-26-218225.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218225.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2026, was $18 million compared to $17.4 million for the quarter ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: PMV Pharma ended the first quarter with $93.5 million in cash, cash equivalents, and marketable securities, compared to $112.9 million as of December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.